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Hippocampal synaptic plasticity is modulated by
neuropeptides, the disruption of which might
contribute to cognitive deficits observed in Alz-
heimer’s disease (AD). Although pro-opiomelanocor-
tin (POMC)-derived neuropeptides and melanocortin
4 receptor (MC4R) are implicated in hippocampus-
dependent synaptic plasticity, how the POMC/
MC4R system functions in the hippocampus and its
role in synaptic dysfunction in AD are largely un-
known. Here, we mapped a functional POMC circuit
in the mouse hippocampus, wherein POMC neurons
in the cornu ammonis 3 (CA3) activate MC4R in
the CA1. Suppression of hippocampal MC4R activity
in the APP/PS1 transgenic mouse model of AD
exacerbates long-term potentiation impairment,
which is alleviated by the replenishment of hippo-
campal POMC/MC4R activity or activation of hippo-
campal MC4R-coupled Gs signaling. Importantly,
MC4R activation rescues amyloid-b-induced synap-
tic dysfunction via a Gs/cyclic AMP (cAMP)/PKA/
cAMP-response element binding protein (CREB)-
dependentmechanism. Hence, disruption of this hip-
pocampal POMC/MC4R circuit might contribute to
synaptic dysfunction observed in AD, revealing a
potential therapeutic target for the disease.INTRODUCTION
Hippocampal synaptic plasticity, manifested as long-term
potentiation (LTP) and long-term depression in the hippocampal
circuit, is believed to be the basis of learning andmemory. LTP in
the hippocampal Schaffer-collateral (SC) pathway, through
which the cornu ammonis 3 (CA3) region sends information to
the CA1 region for integration and processing, is the most well
studied (Malenka and Bear, 2004). Synaptic plasticity in the hip-Cell Repo
This is an open access article under the CC BY-Npocampus is modulated by different types of neuromodulators
from both intrinsic and extrinsic inputs (Lemon and Manahan-
Vaughan, 2006; Lin et al., 2003). Neuropeptides, one of the
two major categories of neuromodulators, play a critical role in
the regulation of neuronal activity. They are secreted from
neural circuit inputs and specifically bind to different G-protein-
coupled receptors; this modulates network activity in the long
term, thus providing functional flexibility to circuits and enabling
neural circuits to generate distinct output patterns (Nusbaum
and Blitz, 2012). Among the various G proteins, G protein a sub-
unit s (Gs) signaling enhances intracellular cyclic AMP (cAMP)-
protein Kinase A (PKA) signaling and subsequently regulates
either a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
(AMPA)-type glutamate receptor trafficking or cAMP-response
element binding protein (CREB)-dependent transcription, both
of which are believed to facilitate synaptic enhancement (Banke
et al., 2000). Disruption of specific neuropeptides such as neuro-
peptide Y disturbs hippocampal neural modulation, conse-
quently impairing hippocampal functions as well as contributing
to cognitive deficits during aging and neurodegenerative disor-
ders such as Alzheimer’s disease (AD) (Borbe´ly et al., 2013).
The hippocampal circuit is one of the first brain regions to be
affected in AD (Saxena and Caroni, 2011), and its dysfunction is
believed to underlie the core features of the cognitive deficits
characteristic of the disease (Palop et al., 2006). In particular,
synaptic dysfunction, which disrupts vulnerable memory-
related networks (La Joie et al., 2014; Selkoe, 2002), precedes
neuronal degeneration and hippocampal atrophy during dis-
ease progression. Specific disruption of neuropeptides has
been reported in the hippocampus in early-stage AD patients
(Kapogiannis and Mattson, 2011; Saxena and Caroni, 2011).
For instance, hippocampal dynorphin level is elevated in AD
patients, contributing to the loss of afferents in the dentate
gyrus (DG) (Ogren et al., 2010). Meanwhile, reduced somato-
statin levels in the cerebral cortex and cerebrospinal fluid
(CSF) have been reported in AD patients (Ogren et al., 2010).
These lines of evidence suggest that neuropeptide-based
modulation of neural circuitry is a possible approach for pro-
tecting the vulnerable hippocampal network and maintaining
cognitive function. Although the involvement of neuropeptidesrts 17, 1819–1831, November 8, 2016 ª 2016 The Author(s). 1819
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Functional POMC Circuit in the Mouse Hippocampus
(A–C) Labeling of pro-opiomelanocortin (POMC) neuron in Pomc-Cremice by intra-hippocampal injection of Cre-dependent GFP adeno-associated virus (AAV).
Cre-dependent GFP AAV and hsyn-mCherry AAV were co-injected to indicate the expression of virus. Serial images of GFP (Pomc; green), mCherry (hsyn; red),
and DAPI (blue) in the dorsal hippocampus (A) and ventral hippocampus (B). Scale bar, 200 mm. (C) Molecular and anatomical characterization of POMC-positive
cells in the CA3 region. Representative images showing co-labeling of Pomc (green) and PCP4. Scale bars, 100 mm (left); 50 mm (right).
(D and E) Quantitative assessment of POMC cell distribution in the mouse hippocampus. (D) Assessment along the mediolateral (ML) axis. (E) Assessment along
the dorsoventral (DV) axis (mean ± SEM; n = 4–6 mice; all coordinates are relative to the bregma).
(F and G) mRNAs of different subregions of the mouse hippocampus were prepared and subjected to real-time PCR. Data are presented as the relative ratio of
mRNA to that of Gapdh: mean ± SEM; n = 4–6 mice. (F) ***p < 0.001, CA1 versus CA2/3. (G) *p < 0.05, CA1 versus CA2/3 (one-way ANOVA with the Bonferroni
post hoc test).
(legend continued on next page)
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in the modulation of hippocampal synaptic plasticity during dis-
ease progression requires further detailed investigation, the
development of circuit-modulating strategies is a promising
strategy for early-stage AD treatment.
Theneuropeptidea-melanocyte-stimulatinghormone (a-MSH),
which is generated from the cleavage of pro-opiomelanocortin
(POMC), plays a well-established role in energy hemostasis regu-
lation in the hypothalamus (Millington, 2007). a-MSH activates
melanocortin 4 receptor (MC4R), consequently enhancing the
intracellular secondary messenger cAMP via Gs activation (Barsh
and Schwartz, 2002). AlthoughMC4R is prominently expressed in
themouse hippocampus (Kishi et al., 2003), its physiological func-
tions remain unexplored. Administration of a-MSH or its analog
[Nle4,D-Phe7]-a-MSH (NDP-MSH) enhances learning and mem-
ory, and exerts a neuroprotective effect in the hippocampus
(Beckwith et al., 1977; Machado et al., 2010; Sandman et al.,
1980). Furthermore, activation of hippocampal MC4R by exoge-
nous ligand administration enhances synaptic plasticity (Shen
et al., 2013). These findings demonstrate the action of a-MSH/
MC4R signaling in the hippocampus. Therefore, it is important to
determine whether there is a hippocampal melanocortin system
and, if so, how it functions. Importantly, a-MSH levels are reduced
in both the plasma and the CSF of AD patients, suggesting that
a-MSH-based neuromodulation is disrupted (Catania et al.,
2000). Hence, it would beof interest to understand how the hippo-
campalmelanocortin peptide system is regulatedandwhether the
circuit is involved in the synaptic plasticity impairment in the
disease.
Here, we mapped a POMC/MC4R circuit in the mouse
hippocampus, the dysfunction of which causes early synaptic
plasticity impairment in the amyloid precursor protein (APP)/
presenilin 1 (PS1) mouse model of AD. Stimulation of CA3
POMC neurons triggers a-MSH secretion, which activates
MC4R in the postsynaptic CA1 region, demonstrating the exis-
tence of a hippocampal CA3-CA1 POMC circuit. Blockade of
the hippocampal a-MSH/MC4R circuit results in precocious
LTP impairment in these mice, whereas activation of this circuit
reverses the deficit. The positive action of the a-MSH/MC4R
circuit on synaptic functions in this mouse model is mediated
by the postsynaptic activation of Gs/PKA/CREB signaling.
Our findings collectively demonstrate that disruption of the hip-
pocampal a-MSH/MC4R circuit contributes to synaptic impair-
ment in AD.(H and I) Neuronal activity stimulated a-melanocyte-stimulating hormone (a-MSH
or cortical (CTX) slices were treated with high potassium (KCl) for 2 hr. a-MSH relea
normalized to that of the untreated control (*p < 0.05, KCl versus Con in HIP, S
pocampus enhanced a-MSH secretion. The specific expression of hM3Dq in hipp
Cre-dependent hM3D-Gq AAV into Pomc-Cremice. CNO administration stimulat
[CNO] versus Con, Student’s t test; n = 3 experiments).
(J and K) CA3 POMC cell activation enhanced GluA1 phosphorylation in anMC4R
in the CA1 region. Co-treatment with HS024 abolished the increased phosphoryl
total GluA1, *p < 0.05, CNO versus control [Con] in vehicle [Veh] condition, #
experiments).
(L andM) Vulnerability of the hippocampal POMC/MC4R circuit in APP/PS1mice.
4 and 6 months of age. Data are presented as the relative ratio of mRNA versus G
t test; n = 6mice per group. (M) Hippocampal a-MSH levels inWT and transgenic (
way ANOVA with the Bonferroni post hoc test; n = 4–6 mice per group).
CA1, cornu ammonis 1; CA2/3, cornu ammonis 2/3; DG, dentate gyrus.RESULTS
Functional POMC Circuit in the Mouse Hippocampus
Wepreviously demonstrated that MC4R activation inmouse hip-
pocampal pyramidal neurons regulates structural and functional
plasticity (Shen et al., 2013). However, it is unknown how
MC4R activation is regulated in the hippocampus at the circuit
level, including the source of the cognate ligand of MC4R
(i.e., a-MSH). As a first step to determine whether a specific hip-
pocampal circuit is involved in MC4R activation, we examined
whether POMC neurons, which generate and secrete a-MSH,
are present in the mouse hippocampus. The POMC cells in the
adult mouse hippocampus were labeled using Pomc-Cre mice,
which express Cre recombinase driven by the Pomc promoter
(McHugh et al., 2007). Recombination of injected AAV9-FLEx-
GFP in the Pomc-Cre mice occurred only in POMC-positive
cells, indicating the localization of POMC-expressing cells
(labeled with GFP) in the mouse hippocampus (Figures 1A–1C).
The POMC-expressing cells were mainly observed in the
CA2/3 pyramidal layers (Figures 1A, 1B, and S1A–S1F). Specif-
ically, staining with the CA2 marker Purkinje cell protein 4
(PCP4) showed that the POMC-expressing cells were mainly
localized in the CA3 region (Figure 1C). Quantitative assessment
of hippocampal POMC cell distribution confirmed that the
POMC cells were mainly confined to the CA3 region of the
dorsal mouse hippocampus; notably, a few POMC cells were
observed in the DG granule cell layer and hilus (Figures 1D, 1E,
and S1G–S1J).
Real-time quantitative PCR analysis was used to confirm the
presence of POMC cells in the mouse hippocampal CA3 region.
Significantly higher levels of Pomc mRNA were detected in the
CA2/3 region comparedwith theCA1 or DG,whereas the highest
Mc4r transcript levels in the hippocampus were found in the CA1
(Figures 1F and 1G). Co-staining with specific neuronal markers
revealed the identity of the POMC cells. Most of the POMC cells
in the CA2/3 were positive for the excitatory neuronal marker cal-
cium/calmodulin-dependent kinase II alpha subunit (CaMKIIa)
but were not co-localized with several inhibitory neuronal
markers (Figures S1A–S1F). Therefore, these cells are CA2/3 py-
ramidal cells. In contrast, the POMC cells in the hilus were pos-
itive for calretinin, but not other inhibitory markers (Figures S1G
and S1H). These results together with the presence of numerous
large dendritic spines at the proximal dendrites suggest that the) secretion from hippocampal POMC cells. (H) Adult mouse hippocampal (HIP)
sed by brain tissues into artificial cerebrospinal fluid (aCSF) was quantified and
tudent’s t test; n = 5 experiments). (I) Firing of POMC cells in the mouse hip-
ocampal POMC-positive cells was achieved by intra-hippocampal injection of
ed the activation of neurons expressing hMC3Dq (*p < 0.05, clozapine-N-oxide
-dependent manner. (J) Hippocampal POMC cell firing enhanced pS845 GluA1
ation (western blot analysis). (K) Quantification of band intensity (pS845 GluA1/
CNO+HS024 versus CNO, one-way ANOVA with the Bonferroni test; n = 3
(L) PomcmRNA levels of different hippocampal subregions in APP/PS1mice at
apdh. *p < 0.05; **p < 0.01 versus respective wild-type (WT) group, Student’s
Tg; i.e., APP/PS1) mice upon aging (*p < 0.05 versus respectiveWT group, one-
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POMC cells in the hilus are mossy cells (Scharfman and Myers,
2013) (Figures S1G–S1J). Thus, the POMC cells in the hippo-
campus are mainly CA3 pyramidal neurons, suggesting that
they may secrete a-MSH and activate MC4R on the CA1 neu-
rons, forming a POMC/MC4R circuit in themouse hippocampus.
To demonstrate that this hippocampal POMC/MC4R circuit is
functional, we determined whether the POMC neurons in the
mouse hippocampus express and secrete a-MSH. The endoge-
nous level of a-MSH in the mouse hippocampus was 1.5-fold
higher than that in the cortex but much lower than that in the
hypothalamus (Figure S2A). Enhanced neuronal firing by high
potassium treatment significantly increased a-MSH secretion
in acute mouse hippocampal slices (Figure 1H). To specifically
induce the selective firing of POMC neurons in the mouse hippo-
campus, we labeled these neurons with the stimulatory mutated
muscarinic G-protein-coupled receptor (hM3D-G protein a sub-
unit q [Gq]; DREADD-Gq [‘‘designer receptors exclusively acti-
vated by designer drugs’’-Gq]), which couples with the Gq
pathway to acutely fire the neurons upon activation by the recep-
tor ligand clozapine-N-oxide (CNO) (Alexander et al., 2009). The
CNO-induced selective firing of the hippocampal POMC neu-
rons significantly increased a-MSH secretion in the acute mouse
hippocampal slices (Figure 1I). We subsequently examined
whether stimulation of the hippocampal POMC neurons, which
triggers a-MSH secretion, can activate postsynaptic MC4Rs.
Accordingly, CNO treatment significantly increased the Ser845
phosphorylation of the AMPA receptor subunit GluA1, a down-
stream target of MC4R signaling (Shen et al., 2013) in the CA1,
by 80% (Figures 1J and 1K). Meanwhile, co-treatment with
the MC4R antagonist HS024 abolished the specific increase of
Ser845 GluA1 phosphorylation (Figures 1J and 1K). Stimulation
of hilar POMC cells did not increase this GluA1 phosphorylation
(Figures S2B and S2C). Furthermore, activation of the CA3
POMC neurons in the acute hippocampal slices from the wild-
type (WT) mice increased the Ser845 phosphorylation of
GluA1, whereas this increase was abolished in the heterozygous
Mc4r null (Mc4rtm1Lowl) mice (Mc4r+/; Figures S2D and S2E).
These results collectively suggest that the stimulation of CA3
POMCneurons resulted in the secretion of a-MSH, which conse-
quently activates MC4R and modulates the functions of its
downstream effector AMPA receptor on the postsynaptic neu-
rons, thus forming a functional ‘‘ligand-receptor system’’ in the
mouse hippocampus.
The a-MSH/MC4R pathway plays an important role in hippo-
campal synaptic functions (Shen et al., 2013). Moreover,
hypothalamic POMC and CSF a-MSH signaling appear to be
attenuated upon aging and in AD (Catania et al., 2000; Yang
et al., 2012). Therefore, we examined the regulation of the hippo-
campal POMC neurons upon aging in WT and APP/PS1 mice.
Whereas Pomc mRNA levels remained relatively unchanged in
different hippocampal subregions (i.e., the CA1, CA2/3, and
DG) in WT mice, they were significantly reduced in the CA2/3 re-
gions of APP/PS1 mice at 4 and 6 months of age, when synaptic
dysfunction begins (Figure 1L). Soluble amyloid-beta oligomers
(Ab), which are generated by the proteolytic cleavage of APP,
are believed to trigger synaptic impairment during AD progres-
sion (Larson and Lesne´, 2012). Treatment with Ab reduced the
Pomc transcript levels in acute hippocampal slices (Figures1822 Cell Reports 17, 1819–1831, November 8, 2016S2F–S2H). To study the functional consequence of the loss of
Pomc transcript in the mouse hippocampus of APP/PS1 mice,
we examined the changes of a-MSH levels in the hippocampus.
Accordingly, a-MSH levels increased significantly in the hippo-
campus of WTmice at9 months of age; however, this increase
was abolished in APP/PS1 mice (Figure 1M).
Perturbed Hippocampal MC4R Signaling Exacerbates
LTP Impairment in APP/PS1 Mice
Because a-MSH/MC4R signaling is attenuated in the hippocam-
pus of APP/PS1 mice at the early stage of hippocampal synaptic
plasticity impairment, we determined whether this decreased
signaling is sufficient to trigger precocious synaptic dysfunction
in younger transgenic (Tg) mice before the onset of the pheno-
type. There was no significant difference in the LTP at SC-CA1
synapses between APP/PS1 and control mice at 4–5 months
of age (Figures 2A–2H), which indicates that there was no synap-
tic plasticity dysfunction in APP/PS1 mice at this age. However,
ablation of POMC cells in the CA3 area by the Cre-mediated
expression of diphtheria toxin receptor (DTR) followed by diph-
theria toxin (DT) injection significantly reduced the magnitude
of LTP at hippocampal SC-CA1 synapses, indicating that
removal of the cells secreting the presynaptic ligands of MC4R
in the hippocampus exacerbates the impairment of synaptic
plasticity in APP/PS1 mice (Figures 2A and 2B). Moreover,
chronic intracerebroventricular (ICV) infusion of selective antag-
onists ofMC4R, including HS024 andMCL 0020, which compete
with the ligand released from presynaptic neurons, also exacer-
bated hippocampal LTP impairment in APP/PS1 mice (Figures
2C, 2D, S3A, and S3B). To demonstrate that postsynaptic
MC4R mediates the POMC/a-MSH/MC4R signaling pathway
in the hippocampus, the MC4R activity in CA1 neurons was
selectively blocked by overexpression of its endogenous inverse
agonist, agouti-related protein (AgRP), which also significantly
reduced LTP magnitude (Figures 2E, 2F, and S3C). Finally,
deletion of postsynaptic MC4R in CA1 by shRNA-mediated
knockdown not only reduced LTP in WT mice, but also further
reduced LTP magnitude in APP/PS1 mice (by 20% versus
WT; Figures 2G, 2H, and S3D–S3G). These results collectively
show that blockade of the POMC/MC4R circuit in the hippocam-
pus accelerates and exacerbates defects in synaptic plasticity in
APP/PS1 mice.
Enhanced Activation of Hippocampal MC4R Rescues
LTP Impairment in APP/PS1 Mice
We subsequently investigated whether stimulation or replenish-
ment of the POMC/MC4R circuit in the hippocampus can rescue
LTP defects in these transgenic mice. Accordingly, ICV infusion
of the MC4R agonist D-tyrosine (D-Tyr) melanotan-II (MTII) in
APP/PS1 mice at 6 months of age, when SC-CA1 LTP impair-
ment is first observed, reversed such synaptic plasticity impair-
ment (Figures 3A and 3B). Although the hippocampal LTP
magnitude in APP/PS1 mice was reduced by 16%, D-Tyr
MTII administration restored the LTP magnitude to that of the
WT controls (Figures 3A and 3B). Next, we determined whether
the beneficial effect of D-Tyr MTII on hippocampal LTP in APP/
PS1 mice is mediated by postsynaptic MC4R activation.
MC4R knockdown in the CA1 region of APP/PS1 mice abolished
Figure 2. Perturbation of POMC/MC4R
Signaling Triggers Early Deficits in Synaptic
Plasticity in an AD Mouse Model
(A and B) Deletion of POMC cells in Tg (APP/PS1)
mice impaired long-term potentiation (LTP) for-
mation induced by high-frequency stimulation
(HFS). Tg mice with DTR expressed in the POMC
cells (Tg/POMC-DTR) and WT control mice (WT/
POMC-DTR) were injected with DT to mediate the
ablation of POMC cells.
(C and D) Intracerebroventricular infusion of
HS024 exacerbated LTP impairment in Tg mice.
(E and F) Virus-mediated overexpression of
agouti-related protein (AgRP) in the mouse hip-
pocampus resulted in LTP impairment in Tg mice
at an earlier age. The hippocampi of 3-month-old
Tg mice were injected with AgRP adeno-associ-
ated virus (AAV) and kept for 7 weeks.
(G and H) Virus-mediated knockdown of MC4R in
the CA1 region of Tg mice triggered the early
development of LTP impairment.
(A–H) LTP in the CA1 of the Schaffer-collateral
pathway was induced by two trains of HFS.
(A, C, E, and G) Summary plot of normalized
field excitatory postsynaptic potential (fEPSP)
slope measurement. (B, D, F, and H) Quantifi-
cation of mean fEPSP slopes as averaged in
the last 10 min of the recording after LTP in-
duction (mean ± SEM). (B) *p < 0.05, Tg/POMC-
DTR DT versus Tg/POMC-DTR vehicle (Veh),
one-way ANOVA with the Bonferroni post hoc
test. (D) **p < 0.01, Tg HS024 versus Tg Veh,
two-way ANOVA. (F) *p < 0.05, Tg AgRP versus
Tg Con. (H) *p < 0.05, WT short hairpin RNA
against Mc4r (shMC4R) versus WT Con; **p <
0.01, Tg shMC4R versus Tg Con, two-way
ANOVA; #p < 0.05, Tg shMC4R versus WT
shMC4R, one-way ANOVA with the Bonferroni
post hoc test.the D-Tyr MTII-stimulated enhancement of SC-CA1 LTP (Figures
3C and 3D). We subsequently determined whether replenish-
ment of POMCor its cleavage product, a-MSH, in the hippocam-
pal POMC neurons rescues the LTP impairment in APP/PS1
mice. Specific overexpression of POMC or a-MSH in the
hippocampal POMC neurons of APP/PS1mice under the control
of the Pomc promoter (Figure S4A) restored the impaired LTP in
APP/PS1 mice (Figures 3E, 3F, S4B, and S4E). MC4R knock-
down in the CA1 completely abolished the POMC-mediated
rescue of impaired LTP (Figures 3G and 3H). Hence, the results
indicate that enhanced hippocampal POMC/MC4R signaling
reverses the hippocampal synaptic plasticity impairment in
APP/PS1 mice.Cell ReportMC4R Activation Rescues Defects
in Synaptic Morphology and
Neurotransmission in the
Hippocampus of APP/PS1 Mice
Dendritic spine loss and synaptic dys-
functions are directly associated with
AD pathogenesis and related memory
loss (Selkoe, 2002). Therefore, we inves-tigated whether D-Tyr MTII administration can reverse the
dendritic spine loss and synaptic defects in APP/PS1 mice.
The percentage of mature dendritic spines and spine width in
the hippocampal CA1 stratum radiatum region were significantly
reduced in 6-month-old APP/PS1 mice; moreover, 4 weeks of
ICV infusion of D-Tyr MTII effectively reversed these decreases
(Figures 4A–4C). Furthermore, 6-month-old APP/PS1 mice ex-
hibited significantly reduced SC-CA1 synaptic transmission
strength as indicated by a decrease in the field excitatory post-
synaptic potential (fEPSP) input-output (I/O) relationship. D-Tyr
MTII infusion reversed the neurotransmission deficit in an
MC4R-dependent manner (Figures 4D and 4E). Thus, the results
indicate that MC4R activation restores dendritic spine losss 17, 1819–1831, November 8, 2016 1823
Figure 3. Activation of Hippocampal MC4R
Signaling Rescues LTP Impairment in APP/
PS1 Mice
(A and B) Intracerebroventricular infusion of the
MC4R agonist D-Tyr (D-Tyr MTII) for 4 weeks
rescued the LTP impairment in Tg mice at
6 months of age. (C and D) MC4R knockdown
abolished the D-Tyr-induced rescue of hippo-
campal LTP impairment in Tg mice. (E–H) Over-
expression of full-length POMC, specifically in
hippocampal POMC cells, significantly reversed
CA1 LTP impairment in Tg mice (E and F), which
was abolished when MC4R was knocked down in
the CA1 region (G and H). (A, C, E, and G) LTP in
the CA1 of the Schaffer-collateral pathway was
induced by two trains of HFS. (B, D, E, and H)
Quantification of mean fEPSP slopes as averaged
in the last 10 min of the recording after LTP in-
duction (mean ± SEM). (B) #p < 0.05, Tg Veh
versus WT Veh; *p < 0.05, Tg D-Tyr versus Tg Veh,
one-way ANOVA with the Bonferroni post hoc
test. (D) **p < 0.01, Tg D-Tyr versus Tg Veh;
#p < 0.05, Tg + shMC4R D-Tyr versus Tg D-Tyr,
two-way ANOVA. (F) #p < 0.05, Tg control (Con)
versus WT Con; *p < 0.05, Tg POMC versus Tg
Con, one-way ANOVA with the Bonferroni post
hoc test. (H) *p < 0.05, Tg POMC versus Tg
Con, one-way ANOVA with the Bonferroni post
hoc test.and basal synaptic transmission in the hippocampus of APP/
PS1 mice.
Activation of MC4R-Coupled Gs Signaling Rescues LTP
Impairment in APP/PS1 Mice
MC4R belongs to the G-protein-coupled receptor family, which
transduces signals by coupling to the heterotrimeric Gs protein.
Therefore, we determined whether activation of MC4R-coupled
Gs signaling in the postsynaptic CA1 neurons is sufficient to
rescue synaptic plasticity impairment in APP/PS1 mice. To
selectively activate Gs signaling in the hippocampal CA1 neu-
rons, we overexpressed rat M3-muscarinic receptor (rM3D)-Gs
(DREADD-Gs) in the CA1 region (Guettier et al., 2009). Selective1824 Cell Reports 17, 1819–1831, November 8, 2016activation of rM3D-Gs-expressing neu-
rons in acute mouse hippocampal slices
significantly enhanced Gs signaling, as
indicated by increased GluA1 phosphor-
ylation at Ser845 (Figures S5A–S5F).
In vivo activation of rM3D-Gs-expressing
neurons in the hippocampal CA1 region
in APP/PS1mice by CNO injection signif-
icantly reversed the synaptic plasticity
impairment in the transgenic mice at
6 months of age (Figures 5A and 5B).
Besides the activation of Gs/cAMP/
PKA signaling, MC4R can enhance
neuronal activity in a Gs-independent
manner (Alexander et al., 2009; Gha-
mari-Langroudi et al., 2015). Therefore,
we determined whether MC4R on post-synaptic neurons exerts its beneficial action through the modu-
lation of neuronal activity. Direct stimulation or inhibition of the
activity of CA1 postsynaptic neurons through activation of
hM3D-Gq or hM4D-Di, respectively, did not rescue synaptic
plasticity impairment in 6-month-old APP/PS1 mice (Figures
5C, 5D, S5G, and S5H). These results indicate that the activation
of Gs signaling, but not Gq or G protein a subunit i (Gi), rescues
synaptic plasticity impairment in APP/PS1 mice.
Because perturbation of hippocampal MC4R signaling exac-
erbated LTP impairment in APP/PS1 mice (Figure 2), we deter-
mined whether the activation of Gs signaling downstream
of MC4R is sufficient to rescue this impairment. Although
blockade of MC4R in the hippocampus by AgRP overexpression
Figure 4. Activation of Hippocampal MC4R
Signaling Rescues Defects in Synaptic
Morphology and Transmission in APP/PS1
Mice
(A–C) Loss of mature spines in the CA1 region
of APP/PS1 mice was reversed by intra-
cerebroventricular (ICV) infusion of D-Tyr for
4 weeks. (A) Representative images of GFP-ex-
pressing hippocampal CA1 neurons of 6-month-
old mice. Scale bar, 10 mm. (B) Quantification of
percentage of mature spines (n = 40 dendrites
from 3–5 mice, mean ± SEM). ***p < 0.001, Tg
versusWT in Con condition; ###p < 0.001, Tg D-Tyr
versus Tg Con, one-way ANOVA. (C) Cumulative
probability analysis of spine width.
(D and E) Stimulation of MC4R reversed hippo-
campal synaptic transmission impairment in Tg
mice, whereas MC4R knockdown attenuated the
rescue. Input-output (I/O) curves in response to
stimulus in the hippocampal CA1 region of Tg
mice with D-Tyr ICV infusion (D) and D-Tyr ICV
infusion after shMC4R expression in the CA1 re-
gion (E). The input-output curve was measured by
averaging the slope of EPSPs against stimulus
intensity from 5 to 65 mA (n = 20–30 slices from
10–15 mice).exacerbated the LTP impairment in 4-month-old APP/PS1 mice,
specific activation of Gs signaling, but not Gq, attenuated
this impairment (Figures 5E–5H). These results collectively
indicate that the activation of hippocampal MC4R/Gs/PKA
signaling rescues synaptic plasticity impairment in APP/PS1
mice, thus highlighting an important role of the hippocampal
POMC/MC4R circuit in synaptic plasticity impairment during
AD progression.
MC4R Protects Hippocampal Synapses from Ab through
cAMP/PKA Signaling
Ab accumulation in the brain is associated with or possibly
induces the dysfunction of synapses and neural networks,
contributing to the pathogenesis of AD (Palop and Mucke,
2010). Therefore, we determined whether MC4R activation res-
cues Ab-induced hippocampal synaptic impairment. Whereas
Ab treatment reduced SC-CA1 LTP magnitude in acute mouse
hippocampal slices, D-Tyr MTII pretreatment prevented the
decrease of LTP (Figures 6A and 6B).
Ab treatment also reduced synaptic transmission, as reflected
by the decreased miniature excitatory postsynaptic current
(mEPSC) frequency and amplitude in cultured rat hippocampal
neurons; meanwhile, co-treatment with D-Tyr MTII abolished
these reductions (Figures 6C–6E). MC4R stimulation activates
adenylyl cyclase through Gs, which subsequently increases
intracellular cAMP levels and enhances downstream effectors
including PKA and exchange protein directly activated by
cAMP 2 (EPAC) (Balthasar et al., 2005). Accordingly, increasing
cAMP levels by co-treatment with forskolin, an activator of ad-
enylyl cyclase, rescued the Ab-induced reductions of mEPSC
frequency and amplitude in hippocampal neurons, whereas the
EPAC2 activator 8-4-chlorophenylthio- adenosine 3’:5’-cyclic
monophosphate (8 CP-cAMP) did not (Figures 6F–6H). Further-
more, the PKA inhibitor H89 abolished the D-Tyr MTII-mediatedrescue of the Ab-induced reduction of mEPSC (Figures 6I–6K).
These results collectively suggest that activation of the MC4R/
cAMP/PKA signaling pathway protects hippocampal neurons
from or reverses Ab-triggered synaptic impairment. Further-
more, the results suggest that MC4R activation alleviates Ab-in-
duced synaptic dysfunctions, as evidenced by the restoration of
normal synaptic transmission and rescue of synaptic plasticity
impairment.
MC4R Exerts Beneficial Effects in Hippocampal
Neurons via CREB Activation
CREB, a transcription factor and cellular target of PKA signaling,
is essential for memory formation and retention, as well as
neuronal survival. Downregulation of CREB signaling is impli-
cated in the pathology of AD (Mantamadiotis et al., 2002; Pugaz-
henthi et al., 2011). Acute mouse hippocampal slices treated
with Ab, as well as slices from APP/PS1 mouse brains, exhibited
reduced CREB activation, as demonstrated by the decreased
phosphorylation of CREB at Ser133 (Figure 7A–7D). Meanwhile,
D-Tyr MTII treatment restored the CREB signaling in both condi-
tions (Figure 7A–7D), indicating that MC4R mediates the rescue
of synaptic functions in APP/PS1mice probably through the acti-
vation of CREB signaling.
Next, we examined whether CREB signaling is required
for the MC4R-mediated rescue of synaptic functions. Overex-
pression of the two dominant-negative CREB mutants, i.e.,
S133A-CREB (a phosphorylation mutant) and killer CREB
(kCREB) (a DNA-binding mutant) (Sarkar et al., 2007), in
cultured hippocampal neurons abolished the D-Tyr MTII-
mediated rescue of Ab-induced reduction of mEPSC (Figures
7E–7G). Thus, the results indicate that PKA-dependent
activation of CREB and its transcriptional activity are required
for the MC4R-mediated protective effect at the hippocampal
synapses.Cell Reports 17, 1819–1831, November 8, 2016 1825
Figure 5. Activation of MC4R-Coupled Gs
Signaling Rescues Hippocampal LTP
Impairment in APP/PS1 Mice
(A–D) Activation of hippocampal Gs, but not Gq,
signaling reversed LTP impairment in 6-month-old
Tg mice. (E–H) Activation of hippocampal Gs, but
not Gq, signaling reversed the LTP impairment
induced by AgRP overexpression in the hippo-
campus of 4-month-old Tg mice. (A, C, E, and G)
LTP in the CA1 of the Schaffer-collateral pathway
was induced by two trains of HFS. (B, D, F, and H)
Quantification of mean fEPSP slopes as averaged
in the last 10 min of the recording after LTP in-
duction (mean ± SEM). (B) **p < 0.01, rM3D-
Gs CNO versus rM3D-Gs Veh in Tg mice;
###p < 0.001, rM3D-Gs CNO versus GFP CNO in
Tg mice, one-way ANOVA with the Kruskal-Wallis
test. (F) *p < 0.05, AgRP + rM3D-Gs CNO versus
AgRP + rM3D-Gs Veh in Tg mice, one-way
ANOVA with the Kruskal-Wallis test. (D and H)
Results are not significant.DISCUSSION
This study revealed the presence of POMC neurons, which
secrete POMC-derived peptides upon neuronal activity stimula-
tion, in the hippocampal CA3 area. Moreover, activation of
MC4R in the postsynaptic pyramidal neurons in the CA1 region
results in PKA-dependent postsynaptic potentiation, ultimately
enhancing synaptic plasticity. Dysfunction of this hippocampal
POMC/MC4R circuit leads to synaptic plasticity impairment in
an AD mouse model. Together with the previous report that
POMC/a-MSH is reduced in the CSF and temporal lobe of hu-
man AD patients (Catania et al., 2000), our findings suggest1826 Cell Reports 17, 1819–1831, November 8, 2016that perturbation of the hippocampal
POMC/MC4R pathway might, at least in
part, contribute to the observed synaptic
deficits. Importantly, the results of the
present study reveal a molecular target
for the disease, wherein the specific acti-
vation of MC4R by agonist delivery or
replenishment in POMC neurons rescues
the LTP impairment in APP/PS1 mice.
In the hippocampus, information sig-
nals are modulated by various locally
derived neuropeptides, forming the
ligand-receptor system among different
subregions. The MC4R-dependent mod-
ulation of synaptic plasticity is precisely
controlled by the accessibility and
release of a-MSH. Our study reveals
that only a small population of POMC
cells is present in the hippocampal CA3
region; nonetheless, their activation is
sufficient to contribute to a-MSH secre-
tion in the CA1, subsequently regulat-
ing the synaptic functions within the
Schaffer-collateral pathway via MC4R
activation. Neuropeptides are packagedin large dense-core vesicles and released only under strong
neuronal discharge (Zhao et al., 2011). Thus, a-MSH release is
believed to be triggered when there are strong inputs into the
CA3 and not by basal neuronal activity. Indeed, it is possible
that POMC neurons in the CA3 receive multiple inputs including
the perforant pathway from the medial and lateral entorhinal cor-
tex (EC), reciprocal connections with the septum, mossy fiber in-
puts from the DG, and its own outputs fed back as inputs via the
recurrent collaterals (Kesner, 2013). However, given that POMC
neurons are not evenly distributed in the CA3 region but are
mainly localized at the anterior and medial hippocampus, the
POMC circuit may not be a general intrinsic circuit within the
Figure 6. MC4R Signaling Rescues Oligomeric Ab-Induced Synaptic Dysfunctions in Hippocampal Neurons via the cAMP-PKA Pathway
(A and B) Activation of MC4R signaling rescued Ab-induced hippocampal LTP impairment. Acute hippocampal slices were treated with Ab in the presence of
D-Tyr for 2 hr. LTP in the CA1 region of the Schaffer-collateral pathway was subsequently induced by two trains of HFS. (A) Summary plot of normalized fEPSP
slope measurement. (B) Quantification of mean fEPSP slopes as averaged in the last 10 min of the recording after LTP induction (mean ± SEM). *p < 0.05, Ab
versus Veh; #p < 0.05, D-Tyr Ab versus control (Con) Ab, one-way ANOVA with the Bonferroni post hoc test.
(C–K) Activation of MC4R/cAMP/PKA signaling abolished the Ab-induced reduction of spontaneous neurotransmission in cultured hippocampus neurons. (C–H)
Co-treatment with D-Tyr or forskolin (Fsk), but not 8CT-cAMP (8CT), rescued the Ab-induced reduction of miniature excitatory postsynaptic current (mEPSC).
(I–K) The PKA inhibitor H89 abolished the D-Tyr-stimulated rescue of Ab-induced reduction of mEPSC. Cultured hippocampal neurons were treated with D-Tyr or
D-Tyr + H89 in the presence of Ab as indicated. (C, F, and I) Representative mEPSC traces from Ab-stimulated neurons under different treatments. Quantification
of frequency (D, G, and J) and amplitude (E, H, and K) of mEPSCs (mean ± SEM). *p < 0.05; **p < 0.01 versus Veh in Con; #p < 0.05; ##p < 0.01; ###p < 0.001 versus
Ab in Con (or Ab in D-Tyr for J); one-way ANOVA with the Kruskal-Wallis test.hippocampus that secretes a-MSH and non-selectively en-
hances synaptic plasticity in the hippocampus. Besides the
intrinsic inputs, POMC neurons can also be under the controlof some extrinsic afferents, which may send information to the
hippocampus. Such information can be integrated and strength-
ened through the activation of the hippocampal POMC/MC4RCell Reports 17, 1819–1831, November 8, 2016 1827
Figure 7. Activation of MC4R Signaling
Rescues Synaptic Dysfunctions via CREB
Signaling in APP/PS1 Mice
(A–D) MC4R activation restored the high-potas-
sium-stimulated increase of CREB phosphoryla-
tion in acute hippocampal slices incubated with
Ab (A and B) or slices from Tg mice (C and D).
(A and C) CREB phosphorylated at Ser133
(pCREB) staining in the CA1 pyramidal cell layer.
(B and D) Quantification of fluorescence intensity
in the CA1 pyramidal cell layer (mean ± SEM;
n = 6–10 slices from 3–5 mice). (B) **p < 0.01, Ab
versus Veh in control (Con); #p < 0.05, Ab + D-Tyr
versus Ab; one-way ANOVA with the Kruskal-
Wallis test. (D) **p < 0.01, Tg versus WT in Con;
#p < 0.05, Tg + D-Tyr versus Tg; one-way ANOVA
with the Kruskal-Wallis test.
(E–G) The expression of two dominate-negative
CREB mutants (S133A CREB and kCREB) abol-
ished the D-Tyr-stimulated rescue of the Ab-in-
duced reduction of mEPSC in cultured hippo-
campal neurons. (E) Representative mEPSC
traces fromAb-stimulated neurons under different
treatments. Quantification of frequency (F) and
amplitude (G) of mEPSCs (mean ± SEM). (F)
***p < 0.001, Ab versus Veh in Con; #p < 0.05, Ab +
D-Tyr versus Ab; (G) **p < 0.01, Ab versus Veh in
Con; #p < 0.05, Ab + D-Tyr versus Ab; one-way
ANOVA with the Bonferroni post hoc test.circuit. Thus, it would be interesting to know whether the POMC
circuit contributes to communication between intra- and extra-
hippocampal networks.
Although synaptic plasticity at SC-CA1 synapses is vulnerable
in AD (Mattson andMagnus, 2006), we demonstrated that atten-
uation of the hippocampal POMC/MC4R circuit may contribute
to this impaired synaptic plasticity during disease progression.
It is important to examine the underlying cellular mechanisms
contributing to the deficit of the hippocampal POMC circuit in
AD. There are three potential mechanisms. First, decreased
Pomc transcript levels in themouse hippocampus upon Ab treat-
ment or in AD model mice may reflect the loss of hippocampal
POMC neurons and contribute to decreased a-MSH secretion.
Interestingly, Ab has been reported to regulate the transcription
of neuromodulators in human brain slices (Sebollela et al., 2012).
Second, the activity of POMC neurons might be attenuated, re-
sulting in reduced a-MSH secretion during AD progression. The
POMC cells in the hypothalamus are silenced by mechanistic
target of rapamycin (mTOR) signaling during aging (Yang et al.,
2012), and Ab is reported to induce mTOR hyperactivity (Bove´
et al., 2011). Therefore, it would be of interest to examine
whether the reduced activity of hippocampal POMC cells can
be regulated by mTOR signaling in a similar manner. Third, the
loss of external input may contribute to the reduced activity of
the POMC cells in the hippocampus. The CA3 receives inputs1828 Cell Reports 17, 1819–1831, November 8, 2016from different brain regions including
intrinsic inputs from the DG/CA3 and
extrinsic projections from the EC,
septum, and basal forebrain (Kesner,
2013; Le Duigou et al., 2014). Interest-ingly, like the hippocampus, the EC and basal forebrain are
highly vulnerable and suffer damage in the early stage of AD
(Saxena and Caroni, 2011). Therefore, the hippocampal POMC
circuit may connect different brain regions, and dysfunctions of
this circuit might be associated with the ‘‘spread’’ of the circuitry
malfunctions from vulnerable brain regions (e.g., the EC) to the
hippocampus, which ultimately contributes to the global synap-
tic deficits in AD.
Reversing synaptic dysfunctions is a potential therapeutic
strategy to counteract cognitive decline in AD (Selkoe, 2002).
Here, we report that stimulation of the hippocampal POMC/
MC4R circuit rescues synaptic impairment through the activa-
tion of Gs/cAMP/PKA signaling. Similar to MC4R, activation of
other Gs-coupled receptors such as b2-adrenergic receptor pre-
vents Ab-induced hippocampal LTP impairment (Li et al., 2013).
Furthermore, the specific activation of Gs signaling in MC4R-ex-
pressing neurons reverses synaptic impairment, suggesting that
activation of Gs-coupled receptor signaling alleviates synaptic
dysfunctions in AD. Understanding the involvement of specific
G-protein-coupled receptors in mediating synaptic dysfunction
in AD may aid the development of potential therapeutic strate-
gies. Accordingly, systemic administration of G-protein-coupled
receptor agonists, particularly MC4R agonists, exerts a benefi-
cial effect (Giuliani et al., 2014; Ma and McLaurin, 2014). How-
ever, the nonselective activation of melanocortin receptors in
the brain may cause various side effects such as anorexia (Barsh
and Schwartz, 2002). Thus, the results of our study provide a
foundation for an alternative approach to AD treatment, i.e., pro-
tecting or preserving POMCneurons in the hippocampusmay be
more effective than merely administering receptor agonists.
Furthermore, although MC4R activation reverses synaptic
plasticity impairment in AD, MC4R basal activation must be
maintained to prevent the development of synaptic deficits in
the hippocampus. Blockade of hippocampal MC4R activity trig-
gers early synaptic impairment in AD mouse models (Figure 2).
Thus, identifying ways to replenish the stores of POMC-derived
peptides and maintaining MC4R activation is critical for allevi-
ating hippocampal synaptic plasticity impairment. Hence, the
POMC/MC4R circuit is a potential therapeutic target for AD-
associated cognitive dysfunctions.
EXPERIMENTAL PROCEDURES
Chemicals, Antibodies, and Animals
The details of chemicals and antibodies are described in the Supplemental
Experimental Procedures.
The APP/PS1 double-transgenic mice were generated by incorporating a
human/murine APP construct bearing the Swedish double mutation and the
exon-9-deleted PSEN1 mutation (APPswe + PSEN1/dE9) (Jacobsen et al.,
2006). Pomc-Cre mice have Cre recombinase cDNA inserted at the first ATG
transcription start site, ablating the first 30 bp of the Pomc coding sequence
(McHugh et al., 2007). Mc4rtb mice have a loxP-flanked transcriptional block-
ing (loxTB) sequence that prevents transcription and translation from the
endogenous gene (Balthasar et al., 2005). All the transgenic mice were ob-
tained from Jackson Laboratory. Mouse genotype was confirmed by PCR
analysis of tail biopsies. Four to five mice of the same sex were housed per
cagewith a 12-hr light-dark cycle, as well as food andwater ad libitum. Sample
sizes were primarily chosen on the basis of experience with similar types of ex-
periments. All animal procedures were conducted in accordance with the
Guidelines of the Animal Care Facility of Hong Kong University of Science
and Technology (HKUST) and approved by the Animal Ethics Committee of
HKUST.
Virus Preparation, Oligomeric Ab Preparation and Administration,
Real-Time PCR, Immunohistochemical Analysis, and Confocal
Microscopy
The details of the procedures for virus preparation, oligomeric Ab preparation
and administration, real-time PCR, immunohistochemical analysis, and
confocal microscopy are described in the Supplemental Experimental
Procedures.
Stereotaxic Surgery
Surgical procedures were performed as described previously (Fu et al., 2014).
In brief, animals were anesthetized with 2% isoflurane and placed in a stereo-
taxic head frame on a heat pad. Ophthalmic ointment was applied to the eyes
to prevent drying. A midline incision was made down the scalp, and a crani-
otomy was performed with a dental drill. A 10-mL NanoFil Hamilton syringe
(WPI) with a 33-gauge beveledmetal needle was used to infuse virus with ami-
crosyringe pump and its controller (53311; Stoelting Company). Virus was
infused at 100–150 nL/min. After infusion, the needle was kept at the injection
site for 10 min and then withdrawn slowly. All stereotaxic coordinates are
relative to the bregma. The incision was closed with sutures, and the animals
were subcutaneously injected with antibiotics before recovery under a heat
lamp. The details of viral injection are described in the Supplemental Informa-
tion (Table S1).
For osmotic pump infusions, 5-month-old AD transgenic mice were im-
planted with Alzet mini-osmotic pumps (model 1004) set at 0.11 mL/hr for
28 days. The pumps were loaded with either drug or vehicle solvent in artificial
cerebrospinal fluid (aCSF). D-Tyr MTII (D-Tyr), MCL 0020, or HS024 was admin-istered at 2.4, 2.0, and 0.2 nmol/day per mouse, respectively. The mini-os-
motic pumps were adjusted intracerebroventricularly in the right hemisphere.
Tissue Preparation and Microdissection
Adult male C57BL/6Jmice (3months old) were anesthetized, and their brains
were quickly removed, frozen in liquid-nitrogen-chilled isopentane, and stored
at 80C. Brains were cut into 14-mm-thick sagittal sections using a cryostat
at 16C. The sections were fixed by 75% ethanol (20C) and stained with
cresyl violet. The three layers of CA1 and CA3 pyramidal cells, as well as DG
granule cells, were isolated from the dorsal parts of the mouse hippocampus
(1.0–2.0 mm relative to the bregma) using laser capture microdissection (Leica
AS LMD; Leica Microsystems) under a 103 objective with charge-coupled de-
vice (CCD) camera. The hippocampal subregions were then lysed in the
extraction buffer from NucleoSpin RNA kit and stored at 80C.
Hippocampal Slice Preparation and Treatment
Mice were anesthetized and subsequently euthanized by decapitation. The
brain was immediately resected and soaked in ice-cold 95% O2/5% CO2
oxygenated aCSF preparation ([in mM] 124 NaCl, 26 NaHCO3, 10 glucose,
3 KCl, 1.25 NaHPO4, 2 CaCl2, and 2 MgSO4 [pH 7.4, 310 mOsm]). Brain slices
(300–500 mm) were prepared using a vibrating tissue slicer (HM650V; Thermo
Fisher Scientific) and soaked in oxygenated preparation buffer at 32C for 2 hr.
For the a-MSH secretion assay, 6-month-old mice were anesthetized, and
their brains were cut into 0.5-mm-thick sagittal slices with a vibrating tissue
slicer (HM650V; Thermo Fisher Scientific). Hippocampal tissues were then re-
sected and immediately transferred into aCSF and maintained at 34C. The
slices were incubated in 500 mL aCSF for 2 hr and then transferred to aCSF
containing high potassium (KCl was switched from 2.5 to 50 mM and NaCl
from 126.5 to 78.5 mM to maintain tonicity) or aCSF with 1 mM CNO for
2–4 hr. After treatment, the aCSF was collected and subjected to fluorescence
immunoassay for a-MSH (Phoenix Pharmaceuticals) according to the manu-
facturer’s instructions.
For phosphorylated CREB (pCREB) detection, 3-month-old C57 mice or
6-month-old APP/PS1 mice were anesthetized, and their brains were cut
into 300-mm-thick sagittal slices and incubated in aCSF with different
treatment (1 mM D-Tyr MTII, 500 nM Ab) at 34C for 2 hr. The slices were
subsequently transferred to aCSF containing high potassium (KCl was
switched from 2.5 to 90 mM and NaCl from 126.5 to 38.5 mM to maintain
tonicity) for 3 min and returned to the conditional aCSF. One hour after stimu-
lation, the slices were fixed with 4% paraformaldehyde and immunostaining
was performed.
Electrophysiology
Rat hippocampal neurons at 16–20 days in vitro were used to measure
mEPSCs. The cells were treated with 500 nM Ab for 24 hr alone or together
with different drug combinations as indicated (1 mMD-Tyr MTII, 2 mM forskolin,
5 mM rolipram, and 10 mM H89). Whole-cell patch-clamp recordings were
made at room temperature. The external solution comprised (in mM) 110
NaCl, 5 KCl, 2 CaCl2, 0.8 MgCl2, 10 HEPES, and 10 D-glucose (pH 7.4); the in-
ternal solution comprised (inmM) 135CsCl2, 10HEPES, 2MgCl2, 4 NaATP, 0.4
guanosine 5’-triphosphate sodium salt hydrate (NaGTP), and 0.5 EGTA
(pH 7.2). Picrotoxin (200 mM) was included in the external solution to block
GABAergic inhibitory postsynaptic potentials, and tetrodotoxin (0.5 mM)
was added to prevent action-potential-evoked EPSCs. Cells were held at
70 mV for mEPSC recordings. Pipette and series resistances were typically
3–5 and 15–20 MU, respectively. Only recording epochs in which series and
input resistances varied by <10%were analyzed. At least 10 neurons were re-
corded in each experiment.
For LTP recording, brain slices (300 mm) were prepared and soaked in
oxygenated preparation buffer at 32C for 2 hr. The hippocampal regions
were resected and placed on the center of a MED-P210A probe (Panasonic In-
ternational) with 64 embedded recording sites. The slices were then perfused
with oxygenated aCSF at 28C–32C. Extracellular field potentials were re-
corded using a MED64 multichannel recording system, and data were
collected from the dendritic layer of area CA1 at a sampling rate of 10 kHz.
For each slice, the baseline stimulus intensity was set at the level that elicited
40% of the maximum fEPSP response as determined from the input-outputCell Reports 17, 1819–1831, November 8, 2016 1829
curve. The fEPSP responses were recorded for at least 40 min before LTP in-
duction to ensure stability of the response. LTP was induced by two trains of
high-frequency stimulation (100 Hz for 1 s delivered 30 s apart). The LTP
magnitude was quantified as the percentage change in the fEPSP slope
(10%–90%) taken during the 60-min interval after LTP induction.
Quantification and Statistical Analysis
The investigators who collected and analyzed the electrophysiological and
staining data were blinded to the mouse genotypes and treatment conditions.
Error bars in the figures indicate the SEM. All statistical analyses were per-
formed using GraphPad Prism 6. For biochemical experiments, n designates
the number of mouse brains or slice samples per condition; for mEPSC and
LTP measurements, n designates the numbers of neurons and slices, respec-
tively. Statistical significance was assessed by Student’s t test, or one- or two-
way ANOVA where appropriate, followed by the indicated post hoc tests. All
experiments were performed at least three times, except where indicated.
The level of significance was set at p < 0.05.
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